View Post

Enobosarm Shows Clinical Benefit in AR+, ER+ Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Gina Mauro From: Enobosarm demonstrated clinical benefit at varying dose levels in patients with androgen receptor (AR)–positive, estrogen receptor (ER)–positive metastatic breast cancer, according to phase 2 findings of the G200802 study that were presented during the virtual 2020 San Antonio Breast Cancer Symposium.1,2 At the 9-mg and 18-mg doses of enobosarm, the 6-month clinical benefit rate (CBR) …